PEStore

Venture Capital

Epidarex Capital

Epidarex Capital backs early-stage and high-growth companies, typically pre-profit, from United States. It states a focus on healthcare & life sciences.

Disclosed holdings37
Most recent fund2019
HeadquartersUnited States
Largest single fundNot stated

SEC filings

What Epidarex Capital has raised

From this firm's own Form D filings. A fund files one within fifteen days of its first sale, under penalty of perjury, which makes these the hardest numbers on the page.

Vehicles filed1
Total capital raisedNot disclosed in filings
Largest single vehicleNot disclosed in filings
Filing history2019
Smallest accepted commitmentNone stated
Filed fromMARYLAND

Form D covers US-domiciled vehicles raised from accredited investors. It will not capture a fund raised outside the United States, separately managed accounts, or capital deployed off balance sheet, so treat these as a floor rather than a total.

Regulatory record

How Epidarex Capital is registered

From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.

Adviser statusExempt reporting adviser
Regulatory assets under managementNot reported by an ERA
Private funds advised3 · $17m gross
SEC adviser numberCRD 307874

An exempt reporting adviser is not required to report regulatory assets under management, so the blank above means the question was not asked rather than that the answer is unknown. Where a figure exists it is the gross asset value of the private funds the firm advises, which is a different and usually larger measure.

Portfolio

Disclosed holdings

Companies Epidarex Capital lists on its own website. No investment years are published. 2 have a recorded transaction against them in the deal archive.

CompanyInvestedYears heldRecorded transaction
AdoRx Therapeutics
Apellis
Apellis Pharmaceuticals
Caldan Therapeutics
Clyde Bio
Clyde Biosciences
Confluence Life Sciences$10m 2017
Curve Therapeutics
DUNAD Therapeutics
Edinburgh Molecular Imaging
Enterprise Therapeutics
Epsilogen
Exeed
Harness
Harpoon Medical$100m 2017
Ip3
Kodikaz
Kynos
LUNAC
LUNAC Therapeutics
Lario
Leucid Bio
Libra
Libra Therapeutics
Macomics
Mironid
NodThera
Nyra Medical
RapidPulse
Rapidpulsemed
Ryme Medical
Slate Bio
Theolytics
Topas Therapeutics
dunad.co.uk
edinimage.com
leucid.com

Compiled from Epidarex Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.

Valuation context

Transaction values in Healthcare & Life Sciences

What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.

Median consideration$110m
Middle 50%$30m-$318m
Revenue multiple2.8×
EBITDA multiple12.5×

The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.

For owners

Own a healthcare & life sciences business?

The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.

Request a confidential valuation

For investors

Is this Epidarex Capital?

Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.

Claim or correct this profile

Targeted buyer search

Which hundred of these would actually buy your business?

A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.

See how it works

Comparable investors

Similar mandates

Other venture capital investors active in healthcare & life sciences.